Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human Phase 1/2a Study of BMS-986517 Monotherapy in Advanced Solid Tumors
jRCT2031250420Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2025
01
Overview
Phase 1, open-label trial of BMS-986517 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 2 more (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Part 1 Safety and tolerability of BMS-986517 and determination of RDE and Part 2 Safety and tolerability of BMS-986517 at RDE. Started Nov 2025; status: recruiting.
02
Drugs
BMS-986517
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on jRCT2031250420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250420.